Canopy Growth Is Eyeing Another Reverse Stock Split. Will It Be Enough to Light a Fire Beneath the Beaten-Down Pot Stock?

Canopy Growth shareholders will vote on Sept. 25 on a second reverse stock split after the NASDAQ-listed shares fell back below $1, creating renewed delisting risk. Since its December 2023 reverse split, the stock is down roughly 80% from pre-split levels, although fiscal Q1 2027 revenue rose 13% and its loss narrowed 68% year over year. Approval would help preserve listing status and capital-market access, but the action signals continuing financial stress rather than a fundamental turnaround.

Analysis

A second reverse split within roughly two years is primarily a capital-markets event, not an operating catalyst. For WEED/CGC, preserving Nasdaq access delays the liquidity and financing penalty of OTC trading, but it does not alter the recurring dilution math: any equity raise after the split can rebuild the low-price problem quickly. The relevant near-term variable is not the vote outcome—which is likely—but the authorized split range, post-split float, and whether management couples it with a clearly sized capital raise.

The Sept. 25 vote could create a brief technical bid from retail investors treating a higher nominal share price as a reset, but the prior pattern argues that this demand is fragile. In the following 1-3 months, borrow availability and cost-to-borrow should be monitored: a post-split reduction in share count can temporarily tighten borrow and produce squeezes, particularly if U.S. cannabis reform headlines coincide. That is a trading setup, not a reason to underwrite a durable rerating.

The more consequential 6-18 month issue is funding runway versus cash burn and debt maturities. Better reported losses can reflect accounting, restructuring, or lower non-cash charges rather than self-funded operations; absent sustained positive adjusted EBITDA and operating cash flow, the company remains exposed to equity dilution or expensive refinancing. Canadian licensed producers such as TLRY and ACB may see sympathy flows on reform headlines, but CGC's repeat corporate action makes it the weaker relative-quality expression.

Consensus may overstate delisting as the central downside because approval largely removes that immediate binary risk. The underappreciated risk is that maintaining the listing can facilitate further issuance, shifting the debate from survival to per-share value destruction. No fundamental long is warranted until management provides verifiable quarterly cash-flow improvement and a financing plan that does not materially expand the share count.

Key Decisions for Investors

• Avoid initiating a directional WEED long into the Sept. 25 vote; approval is broadly expected and offers limited upside versus post-split dilution risk. Reassess only after the split ratio and any associated financing are disclosed.
• For a tactical bearish mandate, consider a small 1-3 month long TLRY / short WEED pair after the corporate-action mechanics settle, sized conservatively for cannabis-policy headline risk. Exit if WEED demonstrates two consecutive quarters of positive operating cash flow or if U.S. federal reform produces a sector-wide repricing.
• Set an event alert for a post-vote equity or convert issuance, materially higher authorized shares, or worsening net debt/operating-cash-flow trends; any of these would strengthen the short thesis. Conversely, no short should be added while borrow is constrained or implied volatility prices an outsized squeeze risk.
• Use MSOS—not WEED—as the cleaner vehicle for any U.S. regulatory-reform bullish view over 6-12 months; it avoids company-specific reverse-split and financing risk while retaining exposure to potential U.S. operator rerating.